Medpace Q2 Revenue Jumps 17% to $707M, Backlog Hits $3B, but Legal Clouds Gather
MEDP sits 61% above its 52-week low of $373 on elevated volume (3.1× avg).
Summary
Medpace posted strong Q2 2026 results with 17% revenue growth and a record backlog, but disclosed new securities litigation related to its book-to-bill ratio.
Key Events · Earnings and Guidance · MEDP
-
Q2 Revenue and Earnings Beat
Revenue rose 17.2% to $707.3M, net income jumped 34.5% to $121.4M, and diluted EPS reached $4.25, driven by metabolic and oncology trial growth.
-
Backlog Grows to $3.01B
Backlog increased 4.9% year-over-year to $3.01 billion, with $1.95–$1.97 billion expected to convert to revenue in the next twelve months.
-
New Securities Litigation Disclosed
A class action (filed April 6, 2026) and a derivative suit (filed June 22, 2026) allege misleading statements about the book-to-bill ratio; no liability has been recorded.
-
Aggressive Share Repurchases Continue
The company bought back $294.7M in shares during Q2, with $527M remaining under its authorization, reducing the share count by 1.6% from year-end.
Analysis · MEDP · Industrial Applications And Services
A strong second quarter saw revenue climb 17% to $707.3 million and net income surge 34.5% to $121.4 million, fueled by expanding metabolic and oncology trials. The backlog grew to $3.01 billion, pointing to sustained demand. Yet the 10-Q reveals two new lawsuits—a securities class action and a shareholder derivative suit—alleging misleading statements about the company's book-to-bill ratio. While no liability has been recorded, the litigation introduces uncertainty. During the quarter, $294.7 million in shares were repurchased, with $527 million remaining under the buyback program, highlighting management's confidence in cash generation.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDP was trading at $602.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $17.3B. The 52-week trading range was $373.00 to $677.90. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.